Management Approach of Hypertension with Metabolic Syndrome

Patients with metabolic disorders like Type 2 diabetes mellitus (T2DM), obesity and/or metabolic syndrome (MetS) have a significantly higher prevalence of hypertension, and are increasing in numbers in most parts of the world. This population is often referred to as difficult-to-treat as blood pressure control rates are much lower compared to individuals without these comorbidities.

Current guidelines for the management of hypertension do not provide any specific recommendations for pharmacological strategies among patients with obesity or those with MetS, but recommend the preferential use of a Single-pill combination (SPC) and patient management which takes into account the presence of other cardiovascular risk factors.

Through the expert opinion of two seasoned professors, and a typical case study, we will delve into the pathophysiology of hypertension with metabolic syndrome as well as explore the therapeutic options available to optimally manage these patients.

PROUDLY ORGANIZED AND SPONSORED BY

This was a virtual event happening on Wednesday the 9th of November 2022. The event will be streamed live on this page.

Target Audience: Medical Doctors and Specialists, Consultants, Physician Assistants and other prescribers.

Moderator: Dr Chems-Eddine DJEGHLAL

Time: 1540 GMT (3:40 pm local time)

AGENDA

Wednesday 9th November 2022 (VIRTUAL EVENT) 

3:40 - 3:50 pm: Welcome

3:50 - 4:00 pm: Introduction Sabina BAIDOO

4:00 - 4:40 pm: Part 1 Hypertensive patient with metabolic profiles: A concrete example in case of excess weight Prof. Aleksander PREJBISZ

4:40 – 5:00 pm: Part 2 Which dual single-pill combination in the routine management of hypertensive patients with metabolic profiles in 2022 Prof. Stefano TADDEI

5:00 - 5:20 pm: Panel Discussion (Question and Answer session) All Speakers

5:20 - 5:30 pm: Closing Remarks Sabina BAIDOO